Melredableukin alfa
Based on 1 Customer Validation
Melredableukin alfa (RG7835) is a bivalent conjugate composed of a human IL-2 mutant (T3A, N88D, C125A) and human IgG1. Melredableukin alfa exhibits enhanced Treg cell selectivity in cynomolgus monkey and humanized mouse models. Melredableukin alfa can be used in research related to ulcerative colitis and autoimmune hepatitis.
For research use only. We do not sell to patients.
- Purity : 96.22%
- CAS No.: 2056881-92-4
- Molecular Weight:175.32 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
IC50 & Target
[1]|
IL-2 |
In Vivo
Melredableukin alfa exhibits enhanced Treg cell selectivity in cynomolgus monkey and humanized mouse models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2056881-92-4
-
Appearance Liquid
-
Molecular Weight 175.32 kDa
-
Color Colorless to light yellow
-
SMILES
[Melredableukin alfa]
-
Synonyms
RG7835; RO7049665
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Lykhopiy V, et al. IL-2 immunotherapy for targeting regulatory T cells in autoimmunity". Genes Immun. 2023 Oct;24(5):248-262. [Content Brief]
[2]. Efe O, et al. A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models. J Clin Invest. 2024;134(5):e173107. Published 2024 Mar 1. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Melredableukin alfa
- 2056881-92-4
- RG7835
- RO7049665
- RG 7835
- RG-7835
- RO7049665
- RO 7049665
- RO-7049665
- Interleukin Related
- cynomolgus monkeys
- CD4-positive regulatory T cells
- CD56bright NK cells
- humanized mouse models
- CD8-positive regulatory T cells
- ulcerative colitis
- FOXP3-positive regulatory T cells
- interleukin-2 receptor alpha (CD25)
- immunosuppressive agent
- Treg
- Inhibitor
- inhibitor
- inhibit